The estimated Net Worth of Karen C Lam is at least 140 千$ dollars as of 2 November 2020. Karen Lam owns over 2,022 units of RAPT Therapeutics stock worth over 24,579$ and over the last 5 years Karen sold RAPT stock worth over 115,721$.
Sign up
Karen Lam RAPT stock SEC Form 4 insiders trading
Karen has made over 4 trades of the RAPT Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Karen sold 2,022 units of RAPT stock worth 56,899$ on 2 November 2020.
The largest trade Karen's ever made was exercising 2,777 units of RAPT Therapeutics stock on 12 May 2020 worth over 5,165$. On average, Karen trades about 1,251 units every 30 days since 2020. As of 2 November 2020 Karen still owns at least 12,735 units of RAPT Therapeutics stock.
You can see the complete history of Karen Lam stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Karen Lam's mailing address?
Karen's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at RAPT Therapeutics
Over the last 5 years, insiders at RAPT Therapeutics have traded over 79,325,123$ worth of RAPT Therapeutics stock and bought 4,298,405 units worth 48,553,258$ . The most active insiders traders include Peter Svennilson、David V Goeddel、Fund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of 127,774$. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth 20,456$.
What does RAPT Therapeutics do?
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
What does RAPT Therapeutics's logo look like?
Complete history of Karen Lam stock trades at RAPT Therapeutics
RAPT Therapeutics executives and stock owners
RAPT Therapeutics executives and other stock owners filed with the SEC include:
-
Rodney Young,
Chief Financial Officer -
Brian Wong,
President, Chief Executive Officer, Director -
Dirk Brockstedt,
Chief Scientific Officer -
Dr. Brian Russell Wong M.D., Ph.D.,
CEO, Pres & Director -
Dr. William Ho,
Chief Medical Officer -
Dr. Dirk G. Brockstedt Ph.D.,
Chief Scientific Officer -
Mary Gray,
Independent Director -
Wendye Robbins,
Independent Director -
William Rieflin,
Independent Director -
Linda Kozick,
Independent Director -
Michael Giordano,
Independent Director -
Peter Svennilson,
Director -
William Ho,
Chief Medical Officer -
Lisa Moore,
Vice President - Business Development and Strategy -
Phyllis Gray,
Vice President of Human Resources -
Paul Kassner,
Senior Vice President - Quantitative and Computational Biology -
Dr. David Wustrow,
Sr. VP of Drug Discovery & Preclinical Devel. -
Dr. Paul Kassner,
Sr. VP of Quantitative & Computational Biology -
Steve Young Ph.D.,
VP of Technology -
Rodney K. B. Young,
CFO, Principal Accounting Officer & Sec. -
Group Ii, Lp Column Group I...,
-
Group Ii, Lp Column Group I...,
-
Perkins Caufield & Byers Xv...,
-
David V Goeddel,
Director -
Group Ii, Lp Column Group I...,
-
Group Ii, Lp Column Group I...,
-
Group Ii, Lp Column Group I...,
-
Fund L.P.Topspin Biotech Fu...,
-
Karen C Lam,
VP, Finance and Controller -
Lori Lyons Williams,